Challenger’s board has rejected an indicative $11.80-a-share takeover proposal from TAL Daiichi Life Australia, its largest shareholder, saying the price is not one it could recommend. But it has not slammed the door: the retirement income specialist says it will keep talking to the Japanese-owned insurer about whether a better offer can be reached.

The offer

TAL Daiichi Life Australia (TDA), a subsidiary of Japan’s Daiichi Life Group, lodged a non-binding and conditional proposal after the market closed on Friday 16 October, Challenger disclosed on 19 October. It offered to buy the 79.5% of Challenger shares it does not already own, by way of a scheme of arrangement.

Challenger said the price represented a 17.7% premium to its one-month volume-weighted average share price of $10.03. Reuters reported the proposal valued the company at about $7.94 billion. The approach was subject to due diligence, an agreed scheme implementation deed, regulatory approvals and a board recommendation.

The rejection

On Monday 26 October, Challenger said the board had “carefully considered the offer, having regard to Challenger’s value and prospects” and had “concluded the offer is not at a level it could recommend to shareholders.”

The company added that it “highly values TDA as its largest shareholder and a commercial partner” and that the board intends to engage with TDA to see whether a recommendable proposal can be reached. There is no certainty of a binding offer, and shareholders do not need to take any action.

Chair Duncan West told Financial Standard: “TAL Daiichi Life is Challenger’s largest shareholder and an important commercial partner, and we value that relationship.” He said the board’s responsibility would be “to act in the best interests of Challenger and its shareholders.”

Why now

The approach landed on the same day Challenger reported a strong start to its 2027 financial year. According to Financial Standard, total sales rose 52% on a year earlier to $4.4 billion in the September quarter, annuity sales climbed 72% to $2.8 billion and net annuity flows reached $1.1 billion. Fixed-term annuity sales more than doubled to $2.2 billion, and assets under management rose 5% to $31.9 billion.

Challenger is also reshaping itself. It is merging its Fidante investment management business with Channel Capital, a deal the ACCC has approved, which Financial Standard noted would leave the group more focused on retirement income. In March, the company welcomed APRA’s capital framework for longevity products, and on 2 October it began a $300 million on-market share buy-back.

What to watch

For investors, the board’s language matters. It has rejected the price, not the buyer. The questions now are whether TDA returns with a higher number, whether that number is enough for the board to recommend it, and whether a deal can clear the regulatory approvals the proposal is conditional on.

For the wider market, the approach is a vote of confidence from a major global insurer in Australia’s retirement income market, at a time when more retirees are being encouraged to turn their super balances into a reliable income for life.

Sources: Challenger ASX announcements (19 and 26 October 2026); TAL media release (19 October 2026); Reuters; Financial Standard.